Close this search box.

Tizona searching for new partner after Gilead declines buyout option


Gilead retains ownership of nearly half of Tizona’s equity via $300M investment in 2020, but won’t take full control of anti-HLA-G antibody

By Paul Bonanos, Director of Biopharma Intelligence

February 7, 2024 7:56 PM UTC

Tizona is looking for a partner for its clinical anti-HLA-G antibody in the wake of Gilead’s decision not to exercise its option acquire the biotech under a 2020 deal.

A spokesperson for privately held Tizona Therapeutics Inc. confirmed to BioCentury that Gilead Sciences Inc. (NASDAQ:GILD) “made a strategic business decision to forego its exclusive option to acquire Tizona, while retaining its 49.9% equity interest” in the biotech. Gilead paid Tizona $300 million up front for the equity stake and option…